How much does Takhzyro (Lanadelumab Injection) Cost& price without insurance in China?
Takhzyro® is the commercial brand name of Lanadelumab Injection, a fully human monoclonal antibody developed by Shire. It selectively binds to plasma kallikrein to inhibit its enzymatic activity, lowering bradykinin overproduction and preventing hereditary angioedema attacks.
Main Indications
Routine prophylaxis to prevent recurrent angioedema attacks in adult and adolescent patients aged ≥12 years with hereditary angioedema (HAE).
Common Side Effects
Common mild adverse reactions: Injection-site pain, erythema, headache, dizziness and fatigue.
Laboratory abnormalities: Rare transient liver function fluctuation.
Severe but manageable risks: Severe anaphylactic hypersensitivity reactions after subcutaneous injection.
Approval Status in China
Takhzyro® (Lanadelumab Injection, 300mg/2ml) was officially approved for marketing in China in 2021. It is currently a prescription drug included in China’s Category B medical insurance.
Buy Takhzyro (Lanadelumab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
